Clinical outcomes of lung transplant recipients with telomerase mutations

Sofya Tokman, Jonathan P. Singer, Megan S. Devine, Glen P. Westall, John David Aubert, Michael Tamm, Gregory I. Snell, Joyce S. Lee, Hilary J. Goldberg, Jasleen Kukreja, Jeffrey A. Golden, Lorriana E. Leard, Christine K. Garcia, Steven R. Hays

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background Successful lung transplantation for patients with pulmonary fibrosis from telomerase mutations may be limited by systemic complications of telomerase dysfunction, including myelosuppression, cirrhosis, and malignancy. We describe clinical outcomes in 14 lung transplant recipients with telomerase mutations. Methods Subjects underwent lung transplantation between February 2005 and April 2014 at 5 transplant centers. Data were abstracted from medical records, focusing on outcomes reflecting post-transplant treatment effects likely to be complicated by telomerase mutations. Results The median age of subjects was 60.5 years (interquartile range = 52.0-62.0), 64.3% were male, and the mean post-transplant observation time was 3.2 years (SD ± 2.9). A mutation in telomerase reverse transcriptase was present in 11 subjects, a telomerase RNA component mutation was present in 2 subjects, and an uncharacterized mutation was present in 1 subject. After lung transplantation, 10 subjects were leukopenic and 5 did not tolerate lymphocyte anti-proliferative agents. Six subjects developed recurrent lower respiratory tract infections, 7 developed acute cellular rejection (A1), and 4 developed chronic lung allograft dysfunction. Eight subjects developed at least 1 episode of acute renal failure and 10 developed chronic renal insufficiency. In addition, 3 subjects developed cancer. No subjects had cirrhosis. At data censorship, 13 subjects were alive. Conclusions The clinical course for lung transplant recipients with telomerase mutations is complicated by renal disease, leukopenia with intolerance of lymphocyte anti-proliferative agents, and recurrent lower respiratory tract infections. In contrast, cirrhosis was absent, acute cellular rejection was mild, and development of chronic lung allograft dysfunction was comparable to other lung transplant recipients. Although it poses challenges, lung transplantation may be feasible for patients with pulmonary fibrosis from telomerase mutations.

Original languageEnglish (US)
Pages (from-to)1318-1324
Number of pages7
JournalJournal of Heart and Lung Transplantation
Volume34
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Telomerase
Lung
Mutation
Lung Transplantation
Fibrosis
Pulmonary Fibrosis
Transplants
Respiratory Tract Infections
Allografts
Lymphocytes
Transplant Recipients
Leukopenia
Chronic Renal Insufficiency
Acute Kidney Injury
Medical Records
Neoplasms
Observation
Kidney

Keywords

  • lung transplantation
  • pulmonary fibrosis
  • telomerase mutations
  • telomere
  • telomere syndrome

ASJC Scopus subject areas

  • Transplantation
  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Tokman, S., Singer, J. P., Devine, M. S., Westall, G. P., Aubert, J. D., Tamm, M., ... Hays, S. R. (2015). Clinical outcomes of lung transplant recipients with telomerase mutations. Journal of Heart and Lung Transplantation, 34(10), 1318-1324. https://doi.org/10.1016/j.healun.2015.05.002

Clinical outcomes of lung transplant recipients with telomerase mutations. / Tokman, Sofya; Singer, Jonathan P.; Devine, Megan S.; Westall, Glen P.; Aubert, John David; Tamm, Michael; Snell, Gregory I.; Lee, Joyce S.; Goldberg, Hilary J.; Kukreja, Jasleen; Golden, Jeffrey A.; Leard, Lorriana E.; Garcia, Christine K.; Hays, Steven R.

In: Journal of Heart and Lung Transplantation, Vol. 34, No. 10, 01.10.2015, p. 1318-1324.

Research output: Contribution to journalArticle

Tokman, S, Singer, JP, Devine, MS, Westall, GP, Aubert, JD, Tamm, M, Snell, GI, Lee, JS, Goldberg, HJ, Kukreja, J, Golden, JA, Leard, LE, Garcia, CK & Hays, SR 2015, 'Clinical outcomes of lung transplant recipients with telomerase mutations', Journal of Heart and Lung Transplantation, vol. 34, no. 10, pp. 1318-1324. https://doi.org/10.1016/j.healun.2015.05.002
Tokman, Sofya ; Singer, Jonathan P. ; Devine, Megan S. ; Westall, Glen P. ; Aubert, John David ; Tamm, Michael ; Snell, Gregory I. ; Lee, Joyce S. ; Goldberg, Hilary J. ; Kukreja, Jasleen ; Golden, Jeffrey A. ; Leard, Lorriana E. ; Garcia, Christine K. ; Hays, Steven R. / Clinical outcomes of lung transplant recipients with telomerase mutations. In: Journal of Heart and Lung Transplantation. 2015 ; Vol. 34, No. 10. pp. 1318-1324.
@article{7101b01c81c14997b752aa44570ec412,
title = "Clinical outcomes of lung transplant recipients with telomerase mutations",
abstract = "Background Successful lung transplantation for patients with pulmonary fibrosis from telomerase mutations may be limited by systemic complications of telomerase dysfunction, including myelosuppression, cirrhosis, and malignancy. We describe clinical outcomes in 14 lung transplant recipients with telomerase mutations. Methods Subjects underwent lung transplantation between February 2005 and April 2014 at 5 transplant centers. Data were abstracted from medical records, focusing on outcomes reflecting post-transplant treatment effects likely to be complicated by telomerase mutations. Results The median age of subjects was 60.5 years (interquartile range = 52.0-62.0), 64.3{\%} were male, and the mean post-transplant observation time was 3.2 years (SD ± 2.9). A mutation in telomerase reverse transcriptase was present in 11 subjects, a telomerase RNA component mutation was present in 2 subjects, and an uncharacterized mutation was present in 1 subject. After lung transplantation, 10 subjects were leukopenic and 5 did not tolerate lymphocyte anti-proliferative agents. Six subjects developed recurrent lower respiratory tract infections, 7 developed acute cellular rejection (A1), and 4 developed chronic lung allograft dysfunction. Eight subjects developed at least 1 episode of acute renal failure and 10 developed chronic renal insufficiency. In addition, 3 subjects developed cancer. No subjects had cirrhosis. At data censorship, 13 subjects were alive. Conclusions The clinical course for lung transplant recipients with telomerase mutations is complicated by renal disease, leukopenia with intolerance of lymphocyte anti-proliferative agents, and recurrent lower respiratory tract infections. In contrast, cirrhosis was absent, acute cellular rejection was mild, and development of chronic lung allograft dysfunction was comparable to other lung transplant recipients. Although it poses challenges, lung transplantation may be feasible for patients with pulmonary fibrosis from telomerase mutations.",
keywords = "lung transplantation, pulmonary fibrosis, telomerase mutations, telomere, telomere syndrome",
author = "Sofya Tokman and Singer, {Jonathan P.} and Devine, {Megan S.} and Westall, {Glen P.} and Aubert, {John David} and Michael Tamm and Snell, {Gregory I.} and Lee, {Joyce S.} and Goldberg, {Hilary J.} and Jasleen Kukreja and Golden, {Jeffrey A.} and Leard, {Lorriana E.} and Garcia, {Christine K.} and Hays, {Steven R.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.healun.2015.05.002",
language = "English (US)",
volume = "34",
pages = "1318--1324",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Clinical outcomes of lung transplant recipients with telomerase mutations

AU - Tokman, Sofya

AU - Singer, Jonathan P.

AU - Devine, Megan S.

AU - Westall, Glen P.

AU - Aubert, John David

AU - Tamm, Michael

AU - Snell, Gregory I.

AU - Lee, Joyce S.

AU - Goldberg, Hilary J.

AU - Kukreja, Jasleen

AU - Golden, Jeffrey A.

AU - Leard, Lorriana E.

AU - Garcia, Christine K.

AU - Hays, Steven R.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background Successful lung transplantation for patients with pulmonary fibrosis from telomerase mutations may be limited by systemic complications of telomerase dysfunction, including myelosuppression, cirrhosis, and malignancy. We describe clinical outcomes in 14 lung transplant recipients with telomerase mutations. Methods Subjects underwent lung transplantation between February 2005 and April 2014 at 5 transplant centers. Data were abstracted from medical records, focusing on outcomes reflecting post-transplant treatment effects likely to be complicated by telomerase mutations. Results The median age of subjects was 60.5 years (interquartile range = 52.0-62.0), 64.3% were male, and the mean post-transplant observation time was 3.2 years (SD ± 2.9). A mutation in telomerase reverse transcriptase was present in 11 subjects, a telomerase RNA component mutation was present in 2 subjects, and an uncharacterized mutation was present in 1 subject. After lung transplantation, 10 subjects were leukopenic and 5 did not tolerate lymphocyte anti-proliferative agents. Six subjects developed recurrent lower respiratory tract infections, 7 developed acute cellular rejection (A1), and 4 developed chronic lung allograft dysfunction. Eight subjects developed at least 1 episode of acute renal failure and 10 developed chronic renal insufficiency. In addition, 3 subjects developed cancer. No subjects had cirrhosis. At data censorship, 13 subjects were alive. Conclusions The clinical course for lung transplant recipients with telomerase mutations is complicated by renal disease, leukopenia with intolerance of lymphocyte anti-proliferative agents, and recurrent lower respiratory tract infections. In contrast, cirrhosis was absent, acute cellular rejection was mild, and development of chronic lung allograft dysfunction was comparable to other lung transplant recipients. Although it poses challenges, lung transplantation may be feasible for patients with pulmonary fibrosis from telomerase mutations.

AB - Background Successful lung transplantation for patients with pulmonary fibrosis from telomerase mutations may be limited by systemic complications of telomerase dysfunction, including myelosuppression, cirrhosis, and malignancy. We describe clinical outcomes in 14 lung transplant recipients with telomerase mutations. Methods Subjects underwent lung transplantation between February 2005 and April 2014 at 5 transplant centers. Data were abstracted from medical records, focusing on outcomes reflecting post-transplant treatment effects likely to be complicated by telomerase mutations. Results The median age of subjects was 60.5 years (interquartile range = 52.0-62.0), 64.3% were male, and the mean post-transplant observation time was 3.2 years (SD ± 2.9). A mutation in telomerase reverse transcriptase was present in 11 subjects, a telomerase RNA component mutation was present in 2 subjects, and an uncharacterized mutation was present in 1 subject. After lung transplantation, 10 subjects were leukopenic and 5 did not tolerate lymphocyte anti-proliferative agents. Six subjects developed recurrent lower respiratory tract infections, 7 developed acute cellular rejection (A1), and 4 developed chronic lung allograft dysfunction. Eight subjects developed at least 1 episode of acute renal failure and 10 developed chronic renal insufficiency. In addition, 3 subjects developed cancer. No subjects had cirrhosis. At data censorship, 13 subjects were alive. Conclusions The clinical course for lung transplant recipients with telomerase mutations is complicated by renal disease, leukopenia with intolerance of lymphocyte anti-proliferative agents, and recurrent lower respiratory tract infections. In contrast, cirrhosis was absent, acute cellular rejection was mild, and development of chronic lung allograft dysfunction was comparable to other lung transplant recipients. Although it poses challenges, lung transplantation may be feasible for patients with pulmonary fibrosis from telomerase mutations.

KW - lung transplantation

KW - pulmonary fibrosis

KW - telomerase mutations

KW - telomere

KW - telomere syndrome

UR - http://www.scopus.com/inward/record.url?scp=84943365560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943365560&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2015.05.002

DO - 10.1016/j.healun.2015.05.002

M3 - Article

VL - 34

SP - 1318

EP - 1324

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 10

ER -